Recent trends in antibody-based oncologic imaging

Sukwinder Kaur, Ganesh Venktaraman, Maneesh Jain, Shantibhusan Senapati, Pradeep K. Garg, Surinder Kumar Batra

Research output: Contribution to journalShort survey

80 Citations (Scopus)

Abstract

Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.

Original languageEnglish (US)
Pages (from-to)97-111
Number of pages15
JournalCancer Letters
Volume315
Issue number2
DOIs
StatePublished - Feb 28 2012

Fingerprint

Antibodies
Nanoshells
Raman Spectrum Analysis
Contrast Media
Single-Domain Antibodies
Single-Chain Antibodies
Quantum Dots
Optical Imaging
Neoplasms
Therapeutics

Keywords

  • Antibody
  • Imaging
  • Optical
  • SPECT
  • Tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recent trends in antibody-based oncologic imaging. / Kaur, Sukwinder; Venktaraman, Ganesh; Jain, Maneesh; Senapati, Shantibhusan; Garg, Pradeep K.; Batra, Surinder Kumar.

In: Cancer Letters, Vol. 315, No. 2, 28.02.2012, p. 97-111.

Research output: Contribution to journalShort survey

Kaur, Sukwinder ; Venktaraman, Ganesh ; Jain, Maneesh ; Senapati, Shantibhusan ; Garg, Pradeep K. ; Batra, Surinder Kumar. / Recent trends in antibody-based oncologic imaging. In: Cancer Letters. 2012 ; Vol. 315, No. 2. pp. 97-111.
@article{a68a22d0f94048d8a61d793252da9b05,
title = "Recent trends in antibody-based oncologic imaging",
abstract = "Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.",
keywords = "Antibody, Imaging, Optical, SPECT, Tumor",
author = "Sukwinder Kaur and Ganesh Venktaraman and Maneesh Jain and Shantibhusan Senapati and Garg, {Pradeep K.} and Batra, {Surinder Kumar}",
year = "2012",
month = "2",
day = "28",
doi = "10.1016/j.canlet.2011.10.017",
language = "English (US)",
volume = "315",
pages = "97--111",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Recent trends in antibody-based oncologic imaging

AU - Kaur, Sukwinder

AU - Venktaraman, Ganesh

AU - Jain, Maneesh

AU - Senapati, Shantibhusan

AU - Garg, Pradeep K.

AU - Batra, Surinder Kumar

PY - 2012/2/28

Y1 - 2012/2/28

N2 - Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.

AB - Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.

KW - Antibody

KW - Imaging

KW - Optical

KW - SPECT

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84355162011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84355162011&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2011.10.017

DO - 10.1016/j.canlet.2011.10.017

M3 - Short survey

C2 - 22104729

AN - SCOPUS:84355162011

VL - 315

SP - 97

EP - 111

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -